Market Neuron Logo
⚠ Disclaimer: This report is generated using AI tools and is for informational purposes only. It does not constitute investment advice. Please consult a registered financial advisor before making any investment decisions.

GLAND - Swing Trade Analysis with AI Signals

Last Updated Time : 20 Dec 25, 07:01 am

Back to Swing Trade List

Swing Trade Rating: 3.7

Stock Code GLAND Market Cap 27,584 Cr. Current Price 1,674 ₹ High / Low 2,131 ₹
Stock P/E 23.8 Book Value 610 ₹ Dividend Yield 1.06 % ROCE 15.8 %
ROE 11.6 % Face Value 1.00 ₹ DMA 50 1,799 ₹ DMA 200 1,803 ₹
Chg in FII Hold 0.51 % Chg in DII Hold -0.23 % PAT Qtr 302 Cr. PAT Prev Qtr 269 Cr.
RSI 31.9 MACD -48.4 Volume 70,622 Avg Vol 1Wk 41,075
Low price 1,200 ₹ High price 2,131 ₹ PEG Ratio -6.94 Debt to equity 0.00
52w Index 50.9 % Qtr Profit Var 7.20 % EPS 70.2 ₹ Industry PE 30.6

📊 GLAND shows moderate potential for swing trading. The fundamentals are stable with fair valuation (P/E 23.8 vs industry 30.6), strong EPS (70.2 ₹), and zero debt. Profit growth is steady (+7.2% QoQ), but technical indicators suggest bearish momentum (RSI 31.9, MACD -48.4). The stock is trading below both its 50 DMA (1,799 ₹) and 200 DMA (1,803 ₹), indicating weakness. Optimal entry would be near 1,630–1,650 ₹. If already holding, consider exiting around 1,850–1,900 ₹ if momentum strengthens.

✅ Positive

⚠️ Limitation

🚨 Company Negative News

No major negative news reported, but weak technicals and reduced domestic investor interest raise caution.

🌟 Company Positive News

Consistent profit growth, strong EPS, zero debt, and rising foreign investor interest highlight resilience.

🏭 Industry

The pharmaceutical industry trades at an average P/E of 30.6. GLAND trades at a discount (23.8), reflecting fair valuation but weak technical momentum.

📌 Conclusion

GLAND is a moderately strong candidate for swing trading with stable fundamentals but weak technicals. Entry near 1,630–1,650 ₹ is optimal. Exit strategy should target 1,850–1,900 ₹ if momentum improves. Caution is advised due to bearish indicators and declining domestic investor interest.

I can also prepare a peer comparison with other pharmaceutical companies trading at discounted valuations to highlight whether GLAND offers stronger swing trade potential than its competitors.

Back to Swing Trade List

NIFTY 50 - Today Top Swing Trade Stock Picks

NEXT 50 - Today Top Swing Trade Stock Picks

MIDCAP - Today Top Swing Trade Stock Picks

SMALLCAP - Today Top Swing Trade Stock Picks